"The launch of Absorica, our third commercial product, represents a
major milestone for Cipher and we look forward to its successful
introduction and growth in the U.S. market," said Larry Andrews,
President and CEO of Cipher.

About Cipher Pharmaceuticals Inc.

Cipher Pharmaceuticals (TSX: DND; OTC: CPHMF) is a growing specialty
pharmaceutical company that commercializes novel formulations of
successful, currently marketed molecules. Cipher's strategy is to
in-license clearly differentiated products, advance them through the
clinical development and regulatory approval stages, and out-license to
international marketing partners. The Company's first product is a
fenofibrate formulation marketed in the United States as Lipofen®.
Cipher's second product, an extended-release tramadol, is marketed in
the United States as ConZip® and in Canada as Durela®. Cipher's third
product, a novel formulation of the acne treatment isotretinoin, was
recently introduced to the U.S. market under the trade name Absorica™.
For more information, please visit www.cipherpharma.com.

Forward-Looking Statements

Statements made in this news release, other than those concerning
historical financial information, may be forward-looking and therefore
subject to various risks and uncertainties. The words "may", "will",
"could", "should", "would", "suspect", "outlook", "believe", "plan",
"anticipate", "estimate", "expect", "intend", "forecast", "objective",
"hope" and "continue" (or the negative thereof), and words and
expressions of similar import, are intended to identify forward-looking
statements. Certain material factors or assumptions are applied in
making forward-looking statements and actual results may differ
materially from those expressed or implied in such statements. Factors
that could cause results to vary include those identified in the
Company's Annual Information Form and other filings with Canadian
securities regulatory authorities. These factors include, but are not
limited to losses; the applicability of patents and proprietary
technology; possible patent litigation; approval of products in the
Company's pipeline; marketing of products; meeting projected drug
development timelines and goals; product liability and insurance;
dependence on strategic partnerships and licensees; concentration of
the Company's revenue; substantial competition and rapid technological
change in the pharmaceutical industry; the publication of negative
results of clinical trials of the Company's products; the ability to
access capital; the ability to attract and retain key personnel;
changes in government regulation or regulatory approval processes;
dependence on contract research organizations; third party
reimbursement; the success of the Company's strategic investments; the
achievement of development goals and time frames; the possibility of
shareholder dilution; market price volatility of securities; and the
existence of significant shareholders. All forward-looking statements
presented herein should be considered in conjunction with such filings.
Except as required by Canadian securities laws, the Company does not
undertake to update any forward-looking statements; such statements
speak only as of the date made.